Researchers to present advanced treatment strategies for eye diseases at NEI symposium

NewsGuard 100/100 Score

The National Eye Institute (NEI), part of the National Institutes of Health (NIH), is bringing together premier researchers who translate molecular and genetic approaches from the laboratory to visual system diseases in the clinic.

NIH director Francis S. Collins, M.D., Ph.D., will deliver a taped keynote address at this two-day event that will feature discussions about cutting-edge treatment strategies as well as the impact of the human genome sequencing on diagnosis and treatment of eye diseases.

What: Translational Research and Vision Symposium

Who:Speakers will include:

  • Paul A. Sieving, M.D., Ph.D., NEI Director
  • Christopher P. Austin, M.D., NIH Chemical Genomics Center
  • Ben Barres, M.D., Ph.D., Stanford University
  • Edward S. Boyden, Ph.D., Massachusetts Institute of Technology
  • Emily Y. Chew, M.D., NEI
  • Hemin R. Chin, Ph.D., NEI
  • Dennis O. Clegg, Ph.D., University of California, Santa Barbara
  • Mark S. Humayun, M.D., Ph.D., University of Southern California
  • Samuel G. Jacobson, M.D., Ph.D., University of Pennsylvania
  • Jay Neitz, Ph.D., University of Washington
  • Maureen Neitz, Ph.D., University of Washington
  • Anand Swaroop, Ph.D., NEI
  • James M. Wilson, M.D., Ph.D., University of Pennsylvania
  • Wai T. Wong, M.D., Ph.D., NEI

When: Thursday, June 24, 2010 from 3:00-5:30 p.m.
Friday, June 25, 2010 from 8:30 a.m.-4:30 p.m.

Where: NIH Clinical Center, Masur Auditorium
10 Center Drive
Bethesda, MD 20892
www.cc.nih.gov/ccc/visitor/maps/south_masur_auditorium.pdf

How:Register to attend at www.nei.nih.gov/anniversary/symposia/research.asp.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema